| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
LY5 has inhibitory effects with IC50 values of 0.52, 0.55, and 1.39 μM on RH30, RD2, and U2OS cancer cells, respectively [1]. In human sarcoma cancer cells, LY5 (0.25-1 μM; 16 h) suppresses STAT3 phosphorylation and causes apoptosis [1]. The phosphorylation of STAT3 elicited by IL-6 is inhibited by LY5 (0.25-1 μM; 5 hours) [1].
|
|---|---|
| ln Vivo |
In vivo development of breast tumors is inhibited by LY5 (5 mg/kg; intraperitoneally given once daily for 21 days) [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: RH30 and EW8 cell lines Tested Concentrations: 0.25-1 μM Incubation Duration: 16 hrs (hours) Experimental Results: 0.5 μM completely inhibits Tyr705 phosphorylation and dose-dependently reduces the formation of P-STAT3. |
| Animal Protocol |
Animal/Disease Models: MDA-MB-231 cancer cells were injected into nude mice [1].
Doses: 5 mg/kg. Route of Administration: intraperitoneal (ip) injection; 5 mg/kg; one time/day; for 21 days. Experimental Results: Inhibited tumor growth and Dramatically diminished tumor size. size. |
| References |
| Molecular Formula |
C15H11N3O4S
|
|---|---|
| Molecular Weight |
329.33
|
| Exact Mass |
329.047
|
| CAS # |
1436382-03-4
|
| PubChem CID |
71680713
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
635.6±65.0 °C at 760 mmHg
|
| Flash Point |
338.2±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.717
|
| LogP |
0.03
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C(C(=O)C=C(C2=O)NC3=CN=CC=C3)C(=C1)S(=O)(=O)N
|
| InChi Key |
GSGMKINCHGAOPK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H11N3O4S/c16-23(21,22)13-5-1-4-10-14(13)12(19)7-11(15(10)20)18-9-3-2-6-17-8-9/h1-8,18H,(H2,16,21,22)
|
| Chemical Name |
5,8-dioxo-6-(pyridin-3-ylamino)naphthalene-1-sulfonamide
|
| Synonyms |
LY5; LY 5; LY-5;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0365 mL | 15.1823 mL | 30.3647 mL | |
| 5 mM | 0.6073 mL | 3.0365 mL | 6.0729 mL | |
| 10 mM | 0.3036 mL | 1.5182 mL | 3.0365 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05706636 | NOT YET RECRUITING | Drug: oral mini pulse Drug: Topical cream Device: targeted phototherapy |
Vitiligo | Cairo University | 2023-02 | Not Applicable |
| NCT01670604 | UNKNOWN STATUS | Drug: 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany) Drug: Tetraspan, B. Braun, Melsungen, Germany |
Urologic Surgical Procedures | Kasr El Aini Hospital | 2012-01 | Phase 4 |
| NCT04098432 | COMPLETED | Drug: Nivolumab Radiation: Stereotactic radiotherapy |
Locally Advanced Unresectable Pancreatic Adenocarcinoma | University Hospital Hradec Kralove | 2018-12-03 | Phase 1 Phase 2 |
| NCT05957146 | NOT YET RECRUITING | Device: Routine hemodialysis | End-stage Kidney Disease | Amsterdam UMC, location VUmc | 2023-08 | |
| NCT03096665 | UNKNOWN STATUS | Diagnostic Test: blood test | Acute Abdomen Cardiovascular Diseases Cerebrovascular Disorders Renal Disease Respiratory Disease |
Hanyang University | 2017-04-01 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
